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I M M U N O L O G Y
IL-10–producing Tfh cells accumulate with age and link 
inflammation with age-related immune suppression
Maha Almanan1, Jana Raynor1*, Ireti Ogunsulire2, Anna Malyshkina1, Shibabrata Mukherjee1, 
Sarah A. Hummel1, Jennifer T. Ingram3, Ankur Saini1,4, Markus M. Xie5, Theresa Alenghat1,4,6,  
Sing Sing Way6,7, George S. Deepe Jr.5, Senad Divanovic1, Harinder Singh1,4, Emily Miraldi1,4,  
Allan J. Zajac3, Alexander L. Dent8, Christoph Hölscher2, Claire Chougnet1,4, David A. Hildeman1,4†
Aging results in profound immune dysfunction, resulting in the decline of vaccine responsiveness previously 
attributed to irreversible defects in the immune system. In addition to increased interleukin-6 (IL-6), we found 
aged mice exhibit increased systemic IL-10 that requires forkhead box P3–negative (FoxP3−), but not FoxP3+, 
CD4+T cells. Most IL-10–producing cells manifested a T follicular helper (Tfh) phenotype and required the Tfh cyto-
kines IL-6 and IL-21 for their accrual, so we refer to them as Tfh10 cells. IL-21 was also required to maintain normal 
serum levels of IL-6 and IL-10. Notably, antigen-specific Tfh10 cells arose after immunization of aged mice, and 
neutralization of IL-10 receptor signaling significantly restored Tfh-dependent antibody responses, whereas 
depletion of FoxP3+ regulatory and follicular regulatory cells did not. Thus, these data demonstrate that immune 
suppression with age is reversible and implicate Tfh10 cells as an intriguing link between “inflammaging” and 
impaired immune responses with age.
INTRODUCTION
Declining adaptive immune function in the elderly leads to increased 
risk and severity of infection, poorer control of cancer, and impaired 
responses to vaccination (1). Paradoxically, aging is also characterized 
by a persistent low-grade immune activation (so-called inflammaging). 
Inflammaging is implicated in several deleterious processes in the 
elderly, including Alzheimer’s disease, cardiovascular diseases, 
and general frailty (2). High levels of circulating, proinflammatory 
interleukin-6 (IL-6) are associated with increased morbidity and 
mortality among older individuals (3).
Paradoxically, alongside increased “inflammaging” is the recent 
observation that serum levels of IL-10, a potent anti-inflammatory 
mediator, are also increased in aged individuals (4), although this is 
somewhat controversial. In addition, an IL-10 genotype (21082GG) 
that is associated with high production of IL-10 in Caucasians is 
more prevalent in centenarians than in younger individuals (65 to 
73 years) (5) and similarly more prevalent in middle-aged controls 
than in age-matched patients with myocardial infarction (6). In 
line with this observation, elderly men with the highest serum 
levels of inflammatory cytokines or with the lowest levels of IL-10 
had the highest risk of frailty-associated pathologies (7). Thus, 
IL-10 levels appear to play an important role in counter-regulation 
of inflammation to promote healthy aging. However, the links 
between inflammaging, IL-10, and immune suppression remain 
largely unexplored.
In contrast to its purported beneficial roles in aging, IL-10 limits 
protective responses to pathogens. IL-10 plays a deleterious role in 
chronic infections, in mice and humans, limiting microbial clearance 
(8). We recently showed that IL-10 fosters reactivation and replica-
tion of cytomegalovirus in the salivary glands of latently infected 
mice (9). Further, IL-10 dampens responses to acute infections or 
vaccines (10). In aged humans, the interferon- (IFN-):IL-10 ratio 
appears to be a critical predictor to protective immunity (11). Despite 
these proposed roles for IL-10 in controlling both systemic inflam-
mation and vaccine responsiveness, little is known about the func-
tion of IL-10, its cellular source, or its molecular control in aged 
animals or humans.
IL-10 can be produced by many cells, including those of the 
innate immune system (notably multiple myeloid cell subsets), the 
adaptive immune system (T cells and B cells), and even nonimmune 
cells (e.g., keratinocytes and hepatocytes) (12). At baseline, in the 
spleen of young mice, the majority of IL-10 expression is localized 
to B cells and CD4+ T cells (both CD25+ and CD25−) (13). In aging, 
a few studies have investigated the cellular sources of IL-10 and sug-
gested a role for memory CD4+ T cells. Early work showed increased 
IL-10 production by aged CD44hiCD4+ T cells (14). The proportion 
of IL-10+ influenza-specific CD4+ T cells increases in aged mice (15). 
In contrast, B cells capable of IL-10 production appear to be decreased 
in older individuals (16). Nonetheless, the major cellular source of 
increased IL-10 in aging remains unclear.
Here, we investigated the cellular sources of IL-10 in aging and 
the relationship between IL-10, inflammaging, and immune suppres-
sion in age. Notably, we found that CD4+FoxP3− cells were required 
for increased systemic IL-10 levels in aging. Further, these IL-10–
producing T cells bore markers of T follicular helper (Tfh) cells and 
were present in both mice and humans. IL-21 was critical for pro-
moting Tfh10 cells, whose absence drove dysregulated systemic 
inflammaging. Last, neutralization of IL-10, but not depletion of 
forkhead box P3–positive (FoxP3+) regulatory T cells (Tregs), restored 
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vaccine-driven B cell responses in aged mice. Together, our data 
show that Tfh10 cells provide a critical link between inflammaging 
and aged-related immune suppression.
RESULTS
Aged mice have increased systemic levels of IL-10
To determine whether IL-10 levels are increased in aged mice, we 
used a sensitive in vivo cytokine capture assay (IVCCA) to measure 
IL-10 in the serum of young versus aged mice (17). This approach 
reflects the actual in vivo steady-state levels of IL-10 as opposed to 
single-snapshot measurement, which is subject to more fluctuation. 
Notably, we found that IL-10 levels were increased two- to threefold 
in the serum of old compared to young mice (Fig. 1A). To assess 
the potential sources of this enhanced IL-10, we examined various 
lymphoid and nonlymphoid tissues and found an increase in IL-10 
mRNA in the epididymal white adipose tissue, lymph nodes, and 
spleen of aged mice compared to young mice (Fig. 1B). These data 
show that the systemic levels of IL-10 are increased with age and that 
secondary lymphoid organs appear to be major contributors of aug-
mented IL-10 expression in aging.
CD4+FoxP3− T cells are the major source of IL-10
To identify cells with enhanced IL-10 production in aged mice, we took 
advantage of IL-10–reporter (VertX) mice, which have an IL-10– 
internal ribosomal entry site (IRES)–enhanced green fluorescent pro-
tein (eGFP) cassette in the endogenous IL-10 locus (13). VertX mice 
allowed us to examine baseline IL-10 production directly ex vivo, in 
the absence of exogenous stimulation, as GFP levels in these mice 
directly correlate with IL-10 production (13). Direct ex vivo flow 
cytometric analysis of spleen cells in aged versus young VertX mice 
revealed a significantly increased frequency of GFP+ (IL-10+) cells 
in multiple cell types, but the largest increase was observed in CD4+ 
T cells (Fig. 1C). In addition, the level of IL-10 produced per cell was 
significantly higher in CD4+ T cells than in CD8+ T cells, CD19−TCR− 
cells, or CD19+ B cells (Fig. 1C). Because FoxP3+ Tregs are a well-known 
source of IL-10 in young mice and their frequency is increased in 
old mice (18), we next determined whether they were the major con-
tributor to this increased IL-10 in aged mice. Staining for FoxP3 in 
VertX mice while maintaining GFP expression is technically infeasible; 
thus, we sorted naïve cells (CD4+CD44loCD62LhiFoxP3GFPneg), 
memory cells (CD4+CD44hiCD62LloFoxP3GFPneg), and Tregs 
(FoxP3GFPpos) from young and aged FoxP3–diphtheria toxin receptor 
(DTR)–GFP mice, stimulated the cells with phorbol 12-myristate 
13-acetate (PMA) and ionomycin (P + I), and measured their pro-
duction of IL-10 by enzyme-linked immunosorbent assay (ELISA). 
As expected, naïve CD4+ T cells produced little IL-10 whether they 
were from young or old mice (Fig. 1D). IL-10 production from 
FoxP3+ Treg was slightly increased in aged mice (~2-fold) (Fig. 1D). 
However, IL-10 production from aged FoxP3− memory T cells was 
increased >10-fold (Fig. 1D). Similarly, flow cytometric analysis of 
spleen cells of wild-type (WT) C57BL/6 mice showed that the fre-
quency of IL-10–producing CD4+FoxP3+ cells was increased slightly 
with age, while IL-10–producing FoxP3−CD4+ T cells were ~10 times 
more frequent with age (Fig. 1E) and expressed the highest levels of 
IL-10 per cell (~2- to 3-fold) compared to their young counterparts 
and aged FoxP3+ cells (fig. S1A).
Together, these three independent approaches show that 
CD4+FoxP3− cells have the highest capacity for IL-10 production in 
Fig. 1. Aged mice have increased systemic levels of IL-10. (A) Serum IL-10 
(means ± SEM) levels in young (4 months, n = 6) and aged (18 months, n = 5) mice, 
representative of four independent experiments. (B) Mean fold change in IL-10 mRNA 
gene expression (means ± SEM) from the spleen, liver, gut, lymph nodes (LNs), inguinal 
white adipose tissue (iWAT), epididymal white adipose tissue (eWAT), and brown 
adipose tissue (BAT) from individual young (2 months, n = 4 to 8) and aged (21 months, 
n = 5 to 9) C57BL/6 mice. Dashed line represents equal aged:young ratio. Data pooled 
from two independent experiments. (C) Splenocytes from young (1.5 months, n = 3) 
and aged (18 months, n = 5) IL-10gfp (VertX) mice were analyzed by flow cytometry. 
Upper graph shows the frequency of cells that are green fluorescent protein–positive 
(GFP+) (means ± SEM). Lower graph shows the average level of GFP expression in 
aged CD4+, CD8+, CD19+, and CD19− that are GFP+ (means ± SEM). (D) IL-10 levels 
(means ± SEM) from phorbol 12-myristate 13-acetate and ionomycin (P + I)–stimulated 
cells sorted from young (3.5 months, n = 4) and aged (24 months, n = 4) FoxP3–internal 
ribosomal entry site (IRES)–diphtheria toxin receptor (DTR)–GFP mice. (E) Gating strategy, 
frequencies, and numbers of FoxP3+ or FoxP3− that are IL-10+ from P + I–stimulated 
splenocytes from young (1.5 months, n = 4) and aged (23 months, n = 4) C57BL/6 
mice (means ± SEM). (F) Serum IL-10 levels (means ± SEM) in young (2.5 months, 
n = 6) and aged (18 months, n = 14) C57BL/6 mice treated with anti-CD4 or isotype 
control or DT-treated FoxP3-DTR mice (19 months, n = 6). Data are pooled from 
two independent experiments. (G) Percentage of FoxP3− splenocytes that are IL-10+ 
(means ± SEM) from aged (18 months, n = 8) and DT-treated FoxP3-DTR (19 months, 
n = 6) mice. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001, Student’s t test. 
MFI, mean fluorescence intensity.
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the spleens of aged mice. In addition, they are required for the in-
creased systemic levels of IL-10, as depletion of >95% of CD4+ T cells 
in the spleens of old mice nearly returned the serum levels of IL-10 
to levels observed in young mice (Fig. 1F). In contrast, depletion of 
FoxP3+ T cells, using FoxP3-DTR mice, increased systemic IL-10 
levels (Fig. 1F). Elevated levels of IL-10 in DT-treated FoxP3-DTR 
mice were associated with an increased frequency of IL-10–producing 
CD4+ T cells (Fig. 1G). Thus, FoxP3−, but not FoxP3+, CD4+ T cells 
are required for the increased systemic levels of IL-10.
Accrual of IL-10–producing CD4+FoxP3− T cells occurs 
in germ-free animals
Recent work has shown that the microbiome changes with age (19). 
Further, alterations in the microbiome can affect IL-10 production 
from CD4+FoxP3+ and FoxP3− T cells (20). To test whether the 
microbiome affects the accumulation of IL-10–producing cells, we 
aged several cohorts of mice in a germ-free facility. The accumula-
tion of IL-10+CD4+FoxP3− cells was similar between age-matched 
mice housed under specific pathogen–free conditions and germ-free 
animals across a range of ages (fig. S1B). Further, the age-driven 
accrual of IL-10–producing cells was consistently observed at four 
different institutions, including the Cincinnati Children’s Hospital, 
the Indiana University/Purdue University Indianapolis, the Univer-
sity of Alabama-Birmingham, and the Research Center Borstel in 
Germany, and it is unlikely that the microbiomes of mice are the 
same at these different institutions. Therefore, age-driven changes to 
the microbiome do not appear to alter the accrual of IL-10–producing 
CD4+FoxP3− T cells.
IL-10–producing CD4+FoxP3− T cells in aged mice are 
predominantly Tfh cells
Several distinct subsets of FoxP3−CD4+ T cells have been reported 
to produce IL-10, predominantly T helper 2 (TH2) cells, type I reg-
ulatory (TR1) T cells, “exTH17” cells, and exTregs (21, 22). Although 
aged IL-10–producing cells expressed lymphocyte activation gene 3 
(LAG3), it is unlikely that they were TR1 cells, as they lacked expression 
of CD49b (fig. S2A), an important marker on TR1 cells (23). Very few 
aged IL-10+CD4+ T cells were capable of IL-4 or IL-17A coproduction, 
ruling out the possibility that these were TH2 or TH17 cells (fig. S2B). 
Next, analysis of IL-17A fate-tracking mice (24) revealed that the frequency 
of exTH17 cells within IL-10+FoxP3−CD4+ T cells from aged mice was ~1% 
(fig. S2C). Analysis of exTregs using FoxP3−CreRosaloxstoploxdTomato 
mice (25) revealed that ~20% of the IL-10+CD4+ T cells were 
dTomato+GFP− “exTregs” in both young and aged mice (fig. S2D). 
Thus, none of TH2, TR1, exTH17, and exTreg make up the bulk of the 
IL-10–producing CD4+ T cells that accumulate in aged mice.
In our investigation of cytokine coproduction by IL-10–producing 
CD4+ T cells, we found that the frequency and total numbers of IL-10+ 
cells that coproduced IL-21 were significantly increased in aged 
compared to young mice (Fig. 2A). As IL-21 is typically produced 
by Tfh cells, we next assessed the frequency of IL-10+CD4+FoxP3− 
T cells that expressed CXCR5 and programmed cell death 1 (PD1), two 
canonical surface markers of Tfh cells, in conjunction with the tran-
scription factor B cell lymphoma 6 (BCL6) (26). Notably, we found 
that most of IL-10+FoxP3−CD4+ T cells were CXCR5+ and PD1+ 
in old mice (Fig. 2B) and expressed BCL6 at levels comparable to 
IL-10−CXCR5+PD1+ Tfh cells in aged mice (fig. S3A). Further, there 
was a progressive age-related accrual of CXCR5+PD1+ Tfh cells, 
including those that produce IL-10 (fig. S3B). Because T follicular 
regulatory (Tfr) cells have been reported to expand with age (27), we 
considered the possibility that IL-10–producing Tfr cells may in-
crease with age. However, we observed that IL-10–producing Tfr 
only marginally increased with age unlike IL-10–producing Tfh cells, 
which increased markedly with age (fig. S3C). Thus, most of the 
IL-10–producing T cells that accumulate with age bore markers of 
Tfh cells, so, for clarity, we will refer to them as Tfh10 cells.
IL-6 is required for Tfh10 generation and systemic increase 
of IL-10 in aged mice
We next examined the role of IL-6 in this system, as IL-6 has been 
reported to (i) control Tfh development (28), (ii) promote IL-10 
production from CD4+ T cells (29), and (iii) act as a key inflammatory 
cytokine that is increased with age (30). To determine whether IL-6 
promotes the accrual of Tfh10 cells with age, we aged IL-6−/− mice 
to ≥17 months and examined the proportion of Tfh10 cells in their 
spleens. While no difference in Tfh cells (including those that pro-
duce IL-10) was observed between young WT and IL-6−/− mice, 
aged IL-6−/− mice exhibited a marked reduction in the frequency of 
Tfh10 cells compared to aged WT mice (Fig. 3, A and B). These data 
show that IL-6 is required for the accrual of Tfh10 cells in aged mice.
Consistent with Tfh10 cells being a major source of IL-10 in vivo, 
we found that systemic levels of IL-10 were significantly decreased 
in aged IL-6−/− mice (Fig. 3C). To determine whether IL-6 was 
required for the development or maintenance of IL-10–producing 
FoxP3−CD4+ T cells, we blocked IL-6 after Tfh cells were formed in 
aged mice and found that neutralization of IL-6 did not reduce the 
frequency or numbers of IL-10–producing cells (Fig. 3D). This was 
not because the anti–IL-6 antibody was not functional, as it was able 
Fig. 2. IL-10–producing FoxP3−CD4+ T cells in aged mice are predominantly 
Tfh cells. (A) Splenocytes from young (2 months, n = 6) and aged (18 months, n = 6) 
C57BL/6 mice were stimulated with P + I, stained with antibodies against TCR, CD8, 
FoxP3, IL-10, and IL-21, and analyzed by flow cytometry. The representative plots 
and graphs show the frequencies and total numbers of IL-21+ cells originating from 
FoxP3−IL10+ cells (means ± SEM). Data are representative of at least two independent 
experiments. (B) Splenocytes from young (2 months, n = 4) and aged (18 months, 
n = 4) C57BL/6 mice were stimulated as above and stained with antibodies against 
TCR, CD8, FoxP3, CXCR5, PD1, and IL-10 and analyzed by flow cytometry. The repre-
sentative plots and graphs show the frequencies and total numbers of CXCR5+PD1+ 
cells originating from FoxP3−IL10+ cells (means ± SEM). *P ≤ 0.05, **P ≤ 0.01, and 
***P ≤ 0.001, Student’s t test.
Almanan et al., Sci. Adv. 2020; 6 : eabb0806     29 July 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
4 of 11
to prevent development of TR1 cells in response to anti-CD3 injec-
tion in vivo as reported previously (29) (fig. S3D). Thus, IL-6 likely 
controls the initial development, rather than the maintenance, that 
contributes to the accrual of Tfh10 cells with age.
IL-21 promotes accumulation of Tfh10 cells and regulates 
the systemic IL-6/IL-10 balance
As IL-21 is a critical cytokine produced by Tfh cells (31), we next 
examined whether IL-6 promoted IL-21 production by CD4+ T cells. 
As expected, consistent with elevated Tfh cells with age, the propor-
tion and absolute number of IL-21+CD4+ T cells was significantly 
increased in aged compared to young mice (Fig. 4A). Notably, in the 
absence of IL-6, the frequency and total numbers of IL-21–producing 
CD4+ T cells were completely abrogated (Fig. 4A). As IL-21 is also 
critical for the development and homeostasis of Tfh cells (32), we 
reasoned that IL-21 could contribute to the accrual of Tfh10 cells 
with age. Similar to aged IL-6−/− mice, the loss of IL-21 prevented 
age-driven accrual of Tfh cells (Fig. 4B), including those that produce 
IL-10 (Fig. 4C). Again, consistent with the loss of Tfh10 cells, levels 
of systemic IL-10 were reduced in aged IL-21−/− mice compared to 
aged WT controls (Fig. 4D). Notably, the levels of IL-6 were in-
creased in IL-21–deficient aged mice (Fig. 4E). Together, these data 
show that IL-21 is critical to balance systemic inflammation (e.g., 
IL-6/IL-10 levels), likely by promoting the accrual of Tfh10 cells. As 
IL-6 and IL-21 have been reported to increase the inducible T cell 
co-stimulator (ICOS) and promote the survival of Tfh cells (33), 
we considered the possibility that increased levels of ICOS on aged 
Tfh cells could be contributing to Tfh10 accumulation. ICOS 
ligand (ICOS-L) neutralization drove a reduction in overall Tfh cell 
number but had no effect on IL-10–producing cells (fig. S4). These 
data show that IL-21 plays a key role in promoting accrual of Tfh10 
cells with age, whose production of IL-10 likely feeds back to 
suppress IL-6.
IL-21 promotes repression of Bim in aged Tfh10 cells, 
leading to their enhanced survival
The accumulation of Tfh10 cells with age could be due to their in-
creased proliferation and/or increased survival. The frequency of 
Tfh10 cells that stained positive for the proliferation marker Ki-67 
actually decreased with age, ruling out the possibility that increased 
proliferation explains their accrual (Fig. 5A). Given our and others’ 
previous data implicating the proapoptotic molecule Bim in aged 
T cell survival (34), we examined the role of Bim in the survival of 
IL-10–producing CD4+ T cells. First, we found that ex vivo aged 
Tfh10 cells survived better than young Tfh cells (Fig. 5B). Second, 
Bim levels were reduced in IL-10–producing CD4+ T cells from aged 
compared to young mice (Fig. 5C). Third, the frequency and total 
number of FoxP3−CD4+ T cells that were IL-10+ were significantly 
increased in Bim-deficient mice, as early as 6 months of age (Fig. 5D). 
Given that IL-21 promotes accumulation of Tfh10 cells, we next de-
termined whether IL-21 contributed to their reduced expression of 
Bim. IL-21 was critical to suppress the levels of Bim within Tfh10 cells, 
which likely contributes to their increased survival (Fig. 5E). Together, 
these data suggest that IL-21–driven suppression of Bim contributes 
to the accumulation of IL-10–producing cells by enhancing their 
survival.
IL-10 limits Tfh-dependent vaccine responses in aged mice
We next sought to determine physiologic relevance of age-driven 
Tfh10 cell accrual. As vaccine responsiveness is a major problem in 
elderly humans and Tfh cells are critical regulators of vaccine re-
sponses (35), we first examined the ability of Tfh cells to produce 
IL-10 in response to vaccination. We bred IL-10eGFP to FoxP3RFP 
mice to generate double-reporter mice, which allowed for efficient 
detection of IL-10 (GFP) and FoxP3 [red fluorescent protein (RFP)] 
while maintaining normal aged-driven Tfh10 accrual (fig. S5A). Old 
and young double-reporter mice were immunized with influenza 
nucleoprotein (NP) in alum, and their NP-specific CD4+ T cells 
Fig. 3. IL-6 is required for Tfh10 cells and for elevated levels of IL-10 in aged mice. 
(A and B) Splenocytes from young (2 months, n ≥ 4 per group) and aged (17 months, 
n ≥ 4 per group) C57BL/6 or IL-6−/− mice were stimulated with P + I, stained with 
antibody against TCR, CD8, CXCR5, PD1, FoxP3, and IL-10 and analyzed by flow 
cytometry. The representative plots and bar graphs show the frequency and total number 
of FoxP3− that are (A) CXCR5+PD1+ and (B) those that produce IL-10 (means ± SEM). 
(C) Aged C57BL/6 (17 months, n = 9) and IL-6−/− (17 months, n = 9) mice were intra-
venously injected with biotinylated anti–IL-10 antibodies, serum was collected 24 hours 
later, and IL-10 levels were measured by ELISA. Graph shows the average serum 
IL-10 (means ± SEM). (D) Aged C57BL/6 mice were treated with isotype control 
(19 months, n = 6) or –IL-6 blocking antibody (19 months, n = 8) on day 0 and eutha-
nized on day 2. Splenocytes were stimulated with P + I, stained with antibody 
against TCR, CD8, PD1, FoxP3, and IL-10, and analyzed by flow cytometry. The rep-
resentative bar graph shows the frequency of FoxP3− that are IL-10+ (means ± SEM). 
*P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001, Student’s t test.
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were assessed by major histocompatibility complex (MHC) tetramer 
staining 8 days later. NP-specific CD4+ T cells emerged after immu-
nization and were predominantly FoxP3− in both young and aged 
mice (Fig. 6A). When we gated on the NP-specific CD4+ T cells, 
there was a significant increase in the frequency of FoxP3−IL-10+ cells 
in aged compared to young mice (Fig. 6A). Further, Tfh cells made 
up the majority of IL-10–producing cells, and their numbers were 
significantly increased in old mice (Fig. 6A). Thus, antigen-specific 
Tfh10 cells emerge following vaccination in aged mice and are the 
dominant population of IL-10–producing T cells.
We next reasoned that if Tfh10 cells were important for regulating 
vaccine responses, then limiting IL-10 signaling should affect vaccine 
responsiveness. To track antigen-specific B cell responses, we used 
a classic nitrophenol-keyhole limpet hemocyanin (NP-KLH) model. 
As reported before (27), we confirmed that aged mice displayed a 
significantly lower level of anti-NP antibody production, as well as 
significantly lower frequency and total numbers of NP-specific B cells 
compared to young mice (fig. S5B). Neutralization of IL-10 receptor 
Fig. 4. IL-21 contributes to accrual of Tfh10 cells and regulates the systemic 
IL-6/IL-10 balance. (A) Splenocytes from young (2.5 months, n ≥ 4 per group) and 
aged (16 months, n ≥ 4 per group) C57BL/6 or IL-6−/− mice were stimulated with 
P + I, stained with antibody against TCR, CD8, FoxP3, and IL-21, and analyzed by 
flow cytometry. Bar graphs show the frequency and total number of FoxP3− that 
are IL-21+ (means ± SEM). (B and C) Splenocytes from young (2 months, n ≥ 4 per 
group) or aged (17 months, n ≥ 3 per group) C57BL/6 or IL-21−/− mice were stimu-
lated as above, stained with antibody against TCR, CD8, CXCR5, PD1, FoxP3, and 
IL-10, and analyzed by flow cytometry. The representative plots and bar graphs 
show the frequency and total number of FoxP3− cells that are (B) CXCR5+PD1+ and 
(C) those that produce IL-10 (means ± SEM). Data are pooled from two independent 
experiments. (D and E) Aged C57BL/6 (17 months, n = 4) and IL-21−/− (17 months, 
n = 3) mice were intravenously injected with biotinylated anti–IL-10 and anti–IL-6 
capturing antibodies, serum was collected 24 hours later, and IL-10 and IL-6 levels 
were measured by ELISA. Graphs show the average serum (D) IL-10 and (E) IL-6 
(means ± SEM). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001, Student’s t test.
Fig. 5. IL-21–driven repression of Bim in aged Tfh10 cells results in their enhanced 
survival. Splenocytes from young (1.5 months, n = 4) and aged (18 months, n = 4) 
mice were stimulated with P + I, stained, and analyzed by flow cytometry. (A) Graph 
shows the frequency of FoxP3− IL-10+ cells that are Ki67+ (means ± SEM). (B) Spleen 
cells were pooled from young (2 months, n = 9) and aged (18 months, n = 6) IL-10gfp 
(VertX) mice, and CXCR5+PD1+GFP+ cells were fluorescence-activated cell sorting 
(FACS)–sorted and cultured. After 15 hours in culture, cells were stained for FoxP3 
and a viability dye. Graph shows the percentage of live cells in gated FoxP3− cells 
(means ± SEM). (C) Splenocytes from young (2 months, n = 4) and aged (18 months, 
n = 4) mice were stimulated as mentioned in (A). Graph shows the level of expres-
sion of Bim in FoxP3−IL-10+ cells (means ± SEM). (D) Splenocytes from 6-month-old 
WT C57BL/6 and Bim−/− mice (n = 6 per group) were stimulated as mentioned in 
(A), stained, and analyzed by flow cytometry. Plots and bar graphs show the frequency 
and total number of FoxP3− that are IL-10+ (means ± SEM). (E) Splenocytes from 
aged (17 months, n = 3 to 4 per group) C57BL/6 or IL-21−/− mice were stimulated as 
mentioned in (A), stained, and analyzed by flow cytometry. Graph shows the levels 
of expression of Bim in FoxP3−CXCR5+PD1+ that are IL-10+ cells (means ± SEM). 
*P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001, Student’s t test.
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(IL-10R) during NP-KLH immunization significantly restored 
anti-NP antibody production as well as the frequency and numbers 
of anti-NP–specific B cells to levels close to those observed in young 
mice (Fig. 6B). Although our data showed that both FoxP3+ Tregs 
and FoxP3+ Tfr cells were only minor producers of IL-10 (Fig. 1D 
and fig. S3C), we nevertheless assessed their contribution to vaccine 
responsiveness using FoxP3-DTR mice. Despite efficient depletion 
of Tfr cells and Tregs (fig. S5C), Treg/Tfr depletion failed to restore 
Fig. 6. IL-10–producing Tfh cells emerge after vaccination, and IL-10, but neither Tregs nor Tfr cells, limits Tfh-dependent vaccine responses in aged mice. 
(A) Plots show IAb-NP tetramer staining in immunized and unimmunized young (3.5 months, n = 5) and aged (18 months, n = 5) IL-10GFP–FOXP3RFP dual-reporter mice. 
Graphs show the frequency and number of NP-specific FoxP3−CD4+ T cells that are IL-10+ and the number of NP-specific FoxP3−IL-10+ T cells that are CXCR5+PD1+ 
(means ± SEM). (B) Aged (17 months, n ≥ 7) WT C57BL/6 (isotype or anti–IL-10) and (20 months, n = 5) FoxP3−DTR [phosphate-buffered saline (PBS)– or DT-treated] mice 
were immunized with nitrophenol-keyhole limpet hemocyanin (NP-KLH) in alum. Plots display the frequency of germinal center (GC) B cells (NP-specific) gated on 
Fas+GL7+. Graphs show the frequency and number of B cells that are IgG1+NP+ (means ± SEM) and serum levels of immunoglobulin (Ig) specific for NP (IgG1) (means ± SEM). 
Data are pooled from two independent experiments. (C to E) Tfh10 cells accumulate during aging in humans. Human spleen cells from young (Y) (median, 18.8; 
range, 18 to 26 years; three males and five females) and old (O) (median, 62; range, 60 to 67 years; four males and four females) individuals were analyzed by flow cytom-
etry. (C) The frequencies of CD3+CD4+CD45RO+FoxP3− that are CXCR5+PD1+ (means ± SEM). (D and E) CD4+ T cells were bead-purified by negative selection; FACS-sorted 
memory CD4+ T cells (CD45RO+) into Tfh cells (CD25−CD127+PD1+CXCR5+), Tregs (CD25+CD127−PD1−CXCR5−), and other memory cells (CD25−CD127+PD1−CXCR5−) were 
either stimulated in vitro with anti-CD3/CD28 beads or unstimulated, and cytokines were analyzed by Luminex (means ± SEM). Each individual is represented by a 
symbol. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001, Student’s t test. BSS, balanced salt solution.
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antibody responses to vaccination (Fig. 6B). Thus, IL-10 limits 
Tfh-dependent B cell responses in aged mice.
Tfh10 cells accumulate during aging in humans
Given the above data in mice showing accumulation of Tfh10 cells 
in aged mice, we next determined whether Tfh10 cells also accumu-
late in aged humans. As Tfh cells are mainly located and function in 
secondary lymphoid organs, we analyzed their proportion in the 
spleens of young and old deceased organ donors with no immuno-
logic condition. The frequency of Tfh cells (CXCR5+PD1+) was in-
creased in aged humans (Fig. 6C). Because flow cytometric analysis of 
cytokines is affected by cryopreservation, we used fluorescence- activated 
cell sorting (FACS) to purify (gating strategy; fig. S6) memory CD4+ 
T cells (CD45RO+) into Tfh cells (CD25−CD127+PD1+CXCR5+), 
Tregs (CD25+CD127−PD1−CXCR5−), and other non-Tfh memory 
cells (CD25−CD127+PD1−CXCR5−) and analyzed their production 
of IL-10 and IL-21 after in vitro restimulation with anti-CD3/CD28 
beads. As expected, IL-21 production was largely limited to Tfh cells 
and was increased with age (Fig. 6D). Notably, the population with 
the highest production of IL-10 was the old Tfh cells (Fig. 6E). Thus, 
in agreement with our data from mice, Tfh10 cells accumulate in aged 
humans. These findings may explain the well-known age-related 
impairment in vaccine responsiveness in the elderly.
DISCUSSION
While there have been many associations between inflammaging 
and immune suppression, our data show a novel linkage between 
these two age-related phenomena. At first glance, the increased levels 
of IL-10 seem counterintuitive to the well-documented increased 
inflammation in aging. However, the concept that both increases in 
both pro- and anti-inflammatory cytokines can coexist has been 
known for many years (36). In addition, these increases in both pro- 
and anti-inflammatory cytokines likely coexist as part of a feedback 
loop in which proinflammatory responses elicit an anti-inflammatory 
response. We found that IL-6 (a hallmark of inflammaging) is critical 
to maintain the elevated levels of IL-10 in aged mice. Further, our 
data suggest that IL-10 production is a feedback mechanism to 
dampen, but not ameliorate, IL-6–driven inflammaging. IL-21 ap-
pears to be critical in maintaining this balance, as mice deficient in 
IL-21 have decreased IL-10 (and loss of Tfh10 cells) but increased 
IL-6. Future work will focus on mechanism(s) by which IL-21 con-
trols this systemic balance between IL-6 and IL-10. Combined, these 
data provide intriguing insight into the complex interplay between 
pro- and anti-inflammation in aging.
Our data are consistent with pro- and anti-inflammation exist-
ing along a continuum that controls age-related disease states. 
For example, increased levels of IL-10 appear to be beneficial in 
limiting frailty, systemic inflammation, and organ dysfunction 
(37). On the other hand, IL-10 and a reduced IFN-:IL-10 ratio 
are correlated with cell-mediated immunity to influenza infection 
and are inversely correlated with the severity of infection (38) 
and also with seroconversion following influenza vaccination (39). 
Thus, on the basis of the association of IL-10 and longevity, it is 
likely that the suppressive effect of IL-10 on systemic inflamma-
tion may be more critical in protecting the aged population from 
inflammation-associated diseases that contribute substantially to 
mortality in the elderly (e.g., cancer and cardiovascular diseases). 
While the negative effect of IL-10 on response to immunization/
infection likely contributes to mortality, it is offset by the notable 
benefit IL-10 offers to mitigate other chronic diseases of the elderly. 
Nonetheless, further work is necessary to understand the mecha-
nism(s) underlying the beneficial versus pathologic effects of IL-10 
in aging.
Our data strongly implicate Tfh10 cells as major contributors to 
the systemically increased levels of IL-10 in aged mice. Depletion of 
CD4+ T cells, but not FoxP3+ Treg, reduces systemic IL-10. Two 
cytokines, IL-6 and IL-21, critical for Tfh homeostasis, are required 
for the emergence of Tfh10 cells and systemic increased IL-10. Con-
sistent with prior work, our data suggest a unique and requisite role 
for each cytokine in Tfh cell homeostasis (40). For instance, our data 
are consistent with IL-6 being required for the development, but not the 
maintenance, of Tfh10 cells. We saw a precipitous loss of Tfh10 cells 
in IL-6–deficient mice but no change in Tfh10 cells when IL-6 was 
neutralized after their formation, similar to a recent study in which 
IL-6 was neutralized during development of a Tfh response in aged 
mice (41). Part of this IL-6–driven developmental program involves 
induction of IL-21 production (42), which our and others’ data 
suggest may be required for the long-term maintenance of Tfh and 
Tfh10 cells (43). Our data also provide some molecular insights into 
the role of IL-21 on maintenance of Tfh10 cells in which we show 
that it is required to suppress their expression of Bim, which regu-
lates their long-term survival. This concept of dual cytokines indi-
vidually promoting TH cell development versus maintenance may 
be a common theme for TH cells, as a similar phenomenon was 
recently observed in TH2 cells with thymic stromal lymphopoietin 
(TSLP) and IL-4 (44).
Two recent papers have also described the existence of IL-10–
producing Tfh cells: one in which the cells appear during chronic 
viral infection in mice (45) and another in which they were found in 
human tonsils (46). Neither appears to have the precise phenotype 
or function, as we describe. The Tfh10 cells arising during chronic 
viral infection appear to promote antibody responses, unlike our 
findings here. One possible explanation for these differences is that 
chronic viral infection alters the Tfh cells or other cells to facilitate their 
ability to enhance B cell responses. While the Tfh10 cells described in 
human tonsils appeared to be functionally similar to ours in that 
they suppressed antibody responses, this suppression was not IL-10 
dependent, and these cells expressed markers distinct from those 
expressed on the Tfh10 cells we describe in aging. Nonetheless, these 
combined data further document the existence of Tfh10 cells, whose 
phenotype and function may vary across disease states (e.g., viral 
infection and aging), and suggest that further work is necessary to 
unravel mechanism(s) by which Tfh10 cells alter immune responses.
Our work is consistent with prior data showing an increase in 
Tfh cells in aged mice (15, 47). These prior studies suggested that 
subtle maturation defects in aged Tfh cells (slightly decreased levels 
of GL7, CXCR5, and ICOS) accounted for their decreased ability to 
provide help to B cells. However, the homing of Tfh cells to germinal 
centers (GCs) was not significantly affected compared to young mice 
when the data were corrected for GC size (15). Further, although 
these authors observed an increase in IL-10–producing CD4+ T cells 
after influenza infection in aged mice, this increase was not attributed 
to Tfh cells but rather to Tregs or Tfr cells (15). However, in our aged 
cohorts of mice, neither Tfr nor Treg appears to be substantial con-
tributors to IL-10 production in vivo. Further, we showed that IL-10 
neutralization, but not Treg/Tfr depletion, largely restored vaccine 
responsiveness in aged mice.
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This IL-10 neutralization would have a similar effect in altering 
the IFN-:IL-10 balance as increasing proinflammatory stimuli to 
restore vaccine responsiveness in aged mice (48). In aged humans, a 
strong proinflammatory adjuvant MF59 was able to significantly 
boost antibody responses to influenza (49). In both studies, increases 
in IFN-–producing CD4+ T cell responses were observed. Com-
bined, these data show that the aged immune system is amenable 
to restoration by manipulating the inflammatory environment. In 
agreement with and extension to the above observations, our 
data suggest that, instead of enhancing proinflammation, transient 
blockade of IL-10 could be a novel strategy to enhance vaccine 
responses in the elderly and, due to its transient nature, is unlikely 
to have untoward effects on autoimmunity, cardiovascular disease, 
or frailty.
Overall, our data add to the accumulating number of defects as-
sociated with the aging immune system, including, but not limited 
to, increased low-level inflammation (50, 51), decreased dendritic 
cell function and activation in GCs (52–54), cell-intrinsic defects in 
lymphocyte signaling (55, 56), and decreased numbers of naïve T cells 
(57, 58). Our data show that active suppression of immune responses 
also occurs with age and can be reversed to enhance immune re-
sponses to vaccination. These data have substantial implications for 
vaccination of elderly populations.
MATERIALS AND METHODS
Mice
Young C57BL/6 mice were purchased from Taconic Biosciences 
(Germantown, NY). Our age classifications were young (<6 months), 
middle age (12 to 15 months), and old (≥18 months) according to 
(59). Ages of mice used in each experiment are described in the figure 
legends. C57BL/6 mice were from the National Institute on Aging 
colony located at Charles River Laboratories (Wilmington, MA). 
FoxP3-IRES-DTR-GFP knock-in C57BL/6 mice (60) were a gift from 
A. Rudensky and were aged in house. Bim-deficient [Bim knockout 
(KO)] mice were originally a gift from P. Bouillet and A. Strasser 
and were bred in-house. IL-6–deficient (IL-6 KO) mice on the 
C57BL/6 background were aged in-house. IL-10–reporter (VertX) 
mice that have the IL-10–IRES-eGFP cassette in the endogenous 
IL-10 locus on the C57BL/6 background (13) were aged in-house. 
IL-10–reporter (VertX) mice were bred to FoxP3-IRES-mRFP mice 
(the Jackson laboratory) to generate IL-10 GFP FoxP3 RFP mice, 
which were aged in house.
Young, middle-aged, and old germ-free mice on the C57BL/6 
background were maintained in isolator units in the Cincinnati Chil-
dren's Hospital Medical Center (CCHMC) Gnotobiotic Mouse Facility. 
Young and aged FoxP3 fate-mapping mice (Foxp3CreRosa26dTomato) 
on the C57BL/6 background were provided by S.S.W. (CCHMC). 
IL-17A fate-tracking mice IL-17CreRosa26eYFP (24) on the C57BL/6 
background were bred and aged under specific pathogen–free con-
ditions in the animal facility of the Research Center Borstel, Germany. 
Young and aged IL-21–deficient (IL-21 KO) mice on the C57BL/6 
background were bred, maintained, and aged in fully accredited 
facilities at the University of Alabama at Birmingham. Spleens 
(controls and IL-21 KO) were shipped overnight on ice and ana-
lyzed in Cincinnati. All animal protocols were reviewed and 
approved by the Institutional Animal Care and Use Committee at 
the Cincinnati Children’s Hospital Research Foundation (IACUC 
2016-0087).
Immunization, neutralization, and depletion treatments
For depletion of FoxP3+ Tregs in old FoxP3-DTR mice, 1.25 g of 
DT per mouse was intraperitoneally injected, and mice were eutha-
nized 2 days later. For CD4 T cell depletion, mice were injected with 
a single dose of 600 g per mouse of anti-CD4 intraperitoneally 
(clone: YTS191, Bio X Cell) or isotype control (clone: LFT-2, Bio X 
Cell) and were euthanized 2 days later. For T cell–dependent immu-
nization, mice were intraperitoneally immunized with 100 g of 
NP-KLH (Biosearch Technologies) mixed with 50% (v/v) alum 
(Thermo Fisher Scientific) and euthanized 10 or 20 days later. For 
IL-10R neutralization, mice were injected with anti–IL-10R block-
ing antibody (clone: 1B1.3A, Bio X Cell) or rat immunoglobulin G1 
(IgG1) isotype control (clone: HRPN, Bio X Cell) at days −1 (1 mg), 
1 (250 g), 3 (500 g), 6 (500 g), and 8 (250 g) and were eutha-
nized 10 days after immunization. For Treg depletion in NP-KLH 
model, mice were immunized as mentioned above, and DT was 
intraperitoneally administered at days −1 (1 g per mouse), 2, 5, 
and 8 (0.25 g per mouse). Mice were euthanized 10 days after im-
munization. For NP immunization, mice were immunized with re-
combinant A/PR/8/34 influenza NP (MyBioSource). Immunizations 
intraperitoneally injected contained 50 g of NP mixed with 50% 
(v/v) alum. For IL-6 neutralization, mice were intraperitoneally in-
jected with 300 g of –IL-6 (clone: MP5-20F3, Bio X Cell) or 300 g 
of isotype control (clone: HRPN, Bio X Cell) on day 0 and euthanized 
on day 2. For ICOS-L neutralization, aged C57BL/6 mice were intra-
peritoneally injected with 150 g of anti–ICOS-L (clone: HK5.3, Bio 
X Cell) or with rat IgG2A isotype control (clone: 2A3, Bio X Cell) 
on days 0, 3, 6, and 9 and then euthanized on day 12.
IVCCA and ELISAs
IL-6 and IL-10 IVCCA was performed as previously described (17) 
using biotinylated capture antibodies (Invitrogen). Briefly, young 
and aged C57BL/6 mice were intravenously injected with 10 g of 
biotinylated anti–IL-6 (MP5-32C11, Invitrogen) and anti–IL-10 
(JES5-16E3, Invitrogen) capture antibodies; mice were bled within 
24 hours, and serum was collected. A luminescent ELISA was per-
formed using anti–IL-6 (MP5-20F3, Invitrogen) or anti–IL-10 
(JES5-2A5, BD Biosciences) as the coating antibody. For NP-specific 
antibody titers, 96-well plates were coated overnight at 4°C with 
NP30-BSA (bovine serum albumin) (Biosearch Technologies), fol-
lowed by blockade of nonspecific binding by incubation for 1 to 
2 hours at 25°C with 5% BSA. Serum samples were loaded into 
plates with eight serial dilutions (starting from 1:100 or 1:1000), fol-
lowed by incubation for 2 hours at 25°C or overnight at 4°C. After 
samples were washed, horseradish peroxidase–conjugated goat anti-
body to mouse IgG1 (PA1-74421, Thermo Fisher Scientific) was added 
to plates, followed by incubation for 2 hours at 25°C. The reactions 
were developed by incubation for 15 min at 37°C with 50 l of 
trimethylboron substrate (BioLegend) and were stopped by the 
addition of 25 l of 10% H3PO4. The plates were read at 450 and 
570 nm (for correction) with an ELISA reader.
Reverse transcription polymerase chain reaction
Samples from different tissues were homogenized, and total cellular 
RNA was extracted and quantified. Deoxyribonuclease-treated RNA 
was then used to synthesize complementary DNA. The primer 
sequences used for detection of IL-10 were 5′-GCTCTTACTGACT-
GGCATGAG-3′ and 5′-CGCAGCTCTAGGAGCATGTG-3′. Expres-
sion levels were normalized to S14 as an internal control gene. The 
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primer sequences used for S14 detection were 5′-GAGGAGTCTG-
GAGACGACGA-3′ and 5′-TGGCAGACACCAAACACATT-3′. 
Quantitative real-time polymerase chain reaction was performed 
with Roche LightCycler 480 SYBR Green 1 Master Mix using the 
Roche LightCycler 480 II instrument (Roche Diagnostics). Each re-
action was performed in triplicate.
Flow cytometry and cell sorting
Human studies
Collection of spleen samples was approved by the CCHMC Institu-
tional Review Board as an exempt research, as individuals were not 
recruited for this study and all samples were deidentified. Only basic 
demographic information and cause of death were shared with the 
researchers. Spleen cells from young (median, 18.8; range, 18 to 
26 years; three males and five females) and old (median, 62; range, 
60 to 67 years; four males and four females) organ donors with no 
immunological condition were rested overnight in RPMI 1640 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin, strepto-
mycin, and glutamine, and 0.5% Hepes at 37°C and 5% CO2. The 
cells were then washed with phosphate-buffered saline (PBS) and 
2% FBS and stained for CD4, CXCR5, PD1, CD45RO (BioLegend), 
CD25 (BD Biosciences), CD3 (Invitrogen), and CD127 (Beckman 
Coulter) for 30 min in 4°C, fixed with 4% para-formaldehyde for 
20 min in 4°C. Cells were stained for FoxP3 (Invitrogen) using 
Invitrogen FoxP3 permeabilization buffer and acquired on a flow 
cytometer. For sorting, CD4+ T cells were bead-purified by negative 
selection from spleen cells and surface-stained with antibodies 
against CD45RO, CD127, CD25, PD1, and CXCR5, and the fol-
lowing populations were sorted by FACS after gating on memory 
CD4+ T cells (CD45RO+): Tfh cells (CD25−CD127+PD1+CXCR5+), 
Tregs (CD25+CD127−PD1−CXCR5−), and non-Tfh memory cells 
(CD25−CD127+PD1−CXCR5−). A total of 10,000 cells were either 
stimulated in vitro with anti-CD3/CD28 beads at a 1:1 cell:bead ratio 
or unstimulated. After 16 hours, supernatants were collected and 
analyzed by Luminex.
Mouse studies
Spleens were harvested and crushed through 100-m filters (BD 
Falcon) to generate single-cell suspensions. A total of 2 × 106 cells 
were plated, incubated with Fc block, and surface-stained with a com-
bination of the following antibodies: CD4, CD8, T cell receptor  
(TCR), LAG3, and Fas (BD Biosciences); CD19, PD1, CXCR5, GL7, 
and CD49b (Invitrogen); and B220, IgG1, and CD44 (BioLegend). 
To identify the NP-specific CD4+ T cells, splenocytes were stained with 
MHC class II NP tetramer (National Institutes of Health). For intra-
cellular staining, cells were intracellularly stained with antibodies 
against Bim (Cell Signaling Technology), Ki67, FoxP3 (Invitrogen), 
and BCL6 (BD Biosciences). For cytokine staining, cells were stimu-
lated with PMA (25 ng/ml) and ionomycin (0.5 g/ml) for 5 hours, 
in the presence of brefeldin A and monensin for the final 4 hours, 
fixed with 2% methanol-free formaldehyde for 1 hour, and then fol-
lowed by intracellular staining for IL-10 (BioLegend), IL-17, and IL-4 
(Invitrogen) using the Invitrogen FoxP3 permeabilization buffer.
For IL-21 staining, cells were fixed, permeabilized with FoxP3 
perm buffer from Invitrogen, and incubated with IL-21R/Fc (R&D 
Systems) chimera for 45 min to 1 hour at 4°C. Cells were then washed 
with perm buffer and stained with Alexa Fluor 488– or Alexa Fluor 
647–conjugated affinity-purified F(ab')2 fragment of goat anti- 
human Fc antibody (Jackson ImmunoResearch Laboratories) for 
45 min to 1 hour at 4°C. Data were acquired on an LSRII, Fortessa II, 
or Fortessa I flow cytometer (BD Biosciences) and analyzed 
using FACSDiva software (BD Biosciences) or FlowJo software 
(FlowJo, Ashland, OR).
For sorting, spleen cells from young (3 months, n = 3) and old 
(≥18 months, n = 4) FoxP3-IRES-DTR-GFP mice were enriched for 
CD4+ T cells using the negative selection magnetic-activated cell 
sorting CD4+ T cell isolation kit II (Miltenyi Biotec, San Diego, 
CA). Enriched cells were stained with anti-CD4, anti-CD44, and 
anti- CD62L antibodies, and the following populations were sort-
ed by a FACSAria (BD Biosciences): CD4+Foxp3GFP+ (Treg), 
CD4+FoxP3−GFP−CD44loCD62Lhi (naïve CD4+), and CD4+FoxP3− 
GFP−CD44hiCD62Llo (memory CD4+). All three populations were 
stimulated with PMA (50 ng/ml) and ionomycin (1 g/ml), and su-
pernatants were collected after 15 hours.
Statistical analysis
Statistical analysis was performed with GraphPad Prism or Excel 
software. Statistical significance was determined by unpaired t test 
or analysis of variance (ANOVA) (as indicated in the figure legends), 
with a significance set at P ≤ 0.05.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/31/eabb0806/DC1
View/request a protocol for this paper from Bio-protocol.
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